Note 9 - Equity Incentive Plan	9 Months Ended
Sep. 30, 2023
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	(9) EQUITY INCENTIVE PLAN: On August 29, 2019, the Company’s stockholders approved the Company’s 2019 Omnibus Equity Incentive Plan at a special meeting of stockholders (the “Incentive Plan”). The Incentive Plan provides for the issuance of up to 68,437 shares of common stock pursuant to the grant of shares of common stock, stock options or other awards, to employees, officers or directors of, and consultants to, the Company and its subsidiaries. Options granted under the Incentive Plan may either be intended to qualify as incentive stock options under the Internal Revenue Code of 1986, or may be non-qualified options, and are exercisable over periods not exceeding ten years from date of grant. As of September 30, 2023, we had awarded 68,437 shares of common stock as awards under the Incentive Plan, with no shares of common stock remaining available for future awards under the Incentive Plan. On June 24, 2021, the Company’s stockholders approved the Company’s 2021 Equity Incentive Plan at its annual meeting of stockholders (the “2021 Plan”). The 2021 Plan provides for the issuance of up to 3,000,000 shares of common stock pursuant to the grant of shares of common stock, stock options or other awards, to employees, officers or directors of, and consultants to, the Company and its subsidiaries. Options granted under the 2021 Plan may either be intended to qualify as incentive stock options under the Internal Revenue Code of 1986, or may be non-qualified options, and are exercisable over periods not exceeding ten years from date of grant. As of September 30, 2023, we had awarded 290,569 shares of common stock and granted options to purchase 792,100 shares of common stock under the 2021 Plan, with 1,917,331 shares of common stock remaining available for future awards. During the three months ended September 30, 2023, the Company granted options to purchase 6,700 shares of common stock to a non-employee director, with an exercise price of $1.26. During the nine months ended September 30, 2023, the Company granted options to purchase (i) an aggregate of 321,631 shares of common stock at exercise prices of $1.28 per share to its officers and employees, (ii) 2,500 shares of common to three employees, with an exercise price of $1.28, (iii) 3,350 shares of common stock to each of the five non-employee directors, with an exercise price of $1.28, and (iv) 113,400 shares of common stock at exercise price of $1.17 to $1.37 per share to a nonemployee and members of the board of directors. Under the option agreements, the options vest either (i) immediately or (ii) 50% at six months and fully vested at twelve months, and have a 10-year term. The options granted during the three and nine months ended September 30, 2023 were valued using the Black Scholes option pricing model using the following assumptions: (i) expected term of 5.00 to 6.25 years; (ii) risk free interest rate of 3.9% - 4.2%; (iii) expected volatility of 101.24% to 103.11%; and (iv) dividend yield of 0.0%. The weighted-average grant date fair value of the options issued by the Company during the three and nine months ended September 30, 2023 ranged from $0.97 to $0.92 per share.

Note 9 - Equity Incentive Plan

9 Months Ended

Sep. 30, 2023

Share-Based Payment Arrangement [Text Block]

(9) EQUITY INCENTIVE PLAN:

On August 29, 2019, the Company’s stockholders approved the Company’s 2019 Omnibus Equity Incentive Plan at a special meeting of stockholders (the “Incentive Plan”). The Incentive Plan provides for the issuance of up to 68,437 shares of common stock pursuant to the grant of shares of common stock, stock options or other awards, to employees, officers or directors of, and consultants to, the Company and its subsidiaries. Options granted under the Incentive Plan may either be intended to qualify as incentive stock options under the Internal Revenue Code of 1986, or may be non-qualified options, and are exercisable over periods not exceeding ten years from date of grant. As of September 30, 2023, we had awarded 68,437 shares of common stock as awards under the Incentive Plan, with no shares of common stock remaining available for future awards under the Incentive Plan.

On June 24, 2021, the Company’s stockholders approved the Company’s 2021 Equity Incentive Plan at its annual meeting of stockholders (the “2021 Plan”). The 2021 Plan provides for the issuance of up to 3,000,000 shares of common stock pursuant to the grant of shares of common stock, stock options or other awards, to employees, officers or directors of, and consultants to, the Company and its subsidiaries. Options granted under the 2021 Plan may either be intended to qualify as incentive stock options under the Internal Revenue Code of 1986, or may be non-qualified options, and are exercisable over periods not exceeding ten years from date of grant. As of September 30, 2023, we had awarded 290,569 shares of common stock and granted options to purchase 792,100 shares of common stock under the 2021 Plan, with 1,917,331 shares of common stock remaining available for future awards.

During the three months ended September 30, 2023, the Company granted options to purchase 6,700 shares of common stock to a non-employee director, with an exercise price of $1.26. During the nine months ended September 30, 2023, the Company granted options to purchase (i) an aggregate of 321,631 shares of common stock at exercise prices of $1.28 per share to its officers and employees, (ii) 2,500 shares of common to three employees, with an exercise price of $1.28, (iii) 3,350 shares of common stock to each of the five non-employee directors, with an exercise price of $1.28, and (iv) 113,400 shares of common stock at exercise price of $1.17 to $1.37 per share to a nonemployee and members of the board of directors. Under the option agreements, the options vest either (i) immediately or (ii) 50% at six months and fully vested at twelve months, and have a 10-year term. The options granted during the three and nine months ended September 30, 2023 were valued using the Black Scholes option pricing model using the following assumptions: (i) expected term of 5.00 to 6.25 years; (ii) risk free interest rate of 3.9% - 4.2%; (iii) expected volatility of 101.24% to 103.11%; and (iv) dividend yield of 0.0%. The weighted-average grant date fair value of the options issued by the Company during the three and nine months ended September 30, 2023 ranged from $0.97 to $0.92 per share.